U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H18N2O4S.C13H20N2O2.H2O
Molecular Weight 588.716
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENICILLIN G PROCAINE

SMILES

O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.[H][C@]23SC(C)(C)[C@@H](N2C(=O)[C@H]3NC(=O)CC4=CC=CC=C4)C(O)=O

InChI

InChIKey=KZDCMKVLEYCGQX-UDPGNSCCSA-N
InChI=1S/C16H18N2O4S.C13H20N2O2.H2O/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9;1-3-15(4-2)9-10-17-13(16)11-5-7-12(14)8-6-11;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);5-8H,3-4,9-10,14H2,1-2H3;1H2/t11-,12+,14-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula C16H18N2O4S
Molecular Weight 334.39
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C13H20N2O2
Molecular Weight 236.3101
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Penicillin G, also known as benzylpenicillin, is a penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms. Microbiology Penicillin G is bactericidal against penicillin-susceptible microorganisms during the stage of active multiplication. It acts by inhibiting biosynthesis of cell-wall mucopeptide. It is not active against the penicillinase-producing bacteria, which include many strains of staphylococci. Penicillin G is highly active in vitro against staphylococci (except penicillinase-producing strains), streptococci (groups A, B, C, G, H, L and M), pneumococci and Neisseria meningitidis. Other organisms susceptible in vitro to penicillin G are Neisseria gonorrhoeae, Corynebacterium diphtheriae, Bacillus anthracis, clostridia, Actinomyces species, Spirillum minus, Streptobacillus monillformis, Listeria monocytogenes, and leptospira; Treponema pallidum is extremely susceptible. Adverse effects can include hypersensitivity reactions including urticaria, fever, joint pains, rashes, angioedema, anaphylaxis, serum sickness-like reaction.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
PENICILLIN G SODIUM

Approved Use

Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued

Launch Date

2001
Curative
PENICILLIN G SODIUM

Approved Use

Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued

Launch Date

2001
Curative
PENICILLIN G SODIUM

Approved Use

Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued

Launch Date

2001
Primary
PENICILLIN G SODIUM

Approved Use

Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued

Launch Date

2001
Primary
PENICILLIN G SODIUM

Approved Use

Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
400 μg/mL
5000000 unit single, intravenous
dose: 5000000 unit
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENICILLIN G serum
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.1 day
1200000 unit single, intramuscular
dose: 1200000 unit
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
PENICILLIN G serum
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
65%
12000000 unit 1 times / day steady-state, intravenous
dose: 12000000 unit
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
PENICILLIN G plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
40%
PENICILLIN G serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Penicillin induced haemolytic anaemia. Communication of a case (author's transl)].
1975
Selection of metalloenzymes by catalytic activity using phage display and catalytic elution.
2001 Apr 2
Substrate binding and catalytic mechanism of class B beta-lactamases: a molecular modelling study.
2001 Dec
Gradient diffusion antibiotic susceptibility testing of potentially probiotic lactobacilli.
2001 Dec
[The use of veterinary drugs during pregnancy of the dog].
2001 Nov 15
[Treatment of acute bacterial meningitis].
2001 Nov 20
[Allergic alteration of leukocytes in patients with drug intolerance].
2001 Sep-Oct
Marked differences in antibiotic use and resistance between university hospitals in Vilnius, Lithuania, and Huddinge, Sweden.
2001 Winter
[Benzylpenicillin efficacy for neutropenic infection prophylaxis in patients with cancer and postcytostatic neutropenia].
2002
Treatment of amatoxin poisoning: 20-year retrospective analysis.
2002
Antibiotics differ in their tendency to cause infusion phlebitis: a prospective observational study.
2002
Treatment of latent syphilis in HIV-infected patients with 10 d of benzylpenicillin G benethamine: a prospective study in Maputo, Mozambique.
2002
[Difficulties with using T lymphocyte culture as a method for diagnosing allergies to benzylpenicillin].
2002
Gateways to Clinical Trials.
2002 Apr
[The Pneumococcal Observatory for the Central Region, 1 April 1999 to 31 March 2000].
2002 Apr
3: Community-acquired pneumonia.
2002 Apr 1
Immunoglobulin E binding determinants on beta-lactam drugs.
2002 Aug
Amoxicillin-induced exanthema in young adults with infectious mononucleosis: demonstration of drug-specific lymphocyte reactivity.
2002 Dec
Cysteine is exported from the Escherichia coli cytoplasm by CydDC, an ATP-binding cassette-type transporter required for cytochrome assembly.
2002 Dec 20
[Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria].
2002 Feb
Controlled administration of penicillin to patients with a positive history but negative skin and specific serum IgE tests.
2002 Feb
Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis.
2002 Feb 1
Chloramphenicol versus benzylpenicillin and gentamicin for the treatment of severe pneumonia in children in Papua New Guinea: a randomised trial.
2002 Feb 9
Comparative in vitro activity of 16 antimicrobial agents against Actinobacillus pleuropneumoniae.
2002 Jan
Natural antibiotic susceptibility and biochemical profiles of Yersinia enterocolitica-like strains: Y. bercovieri, Y. mollaretii, Y. aldovae and 'Y. ruckeri'.
2002 Jan
[Maximum residue levels (MRL's) of veterinary medicines in relation to food safety. MRL's really do matter--the Benzaprocpen case].
2002 Jan 1
The 2.4-A crystal structure of the penicillin-resistant penicillin-binding protein PBP5fm from Enterococcus faecium in complex with benzylpenicillin.
2002 Jul
Liquid chromatographic determination of ampicillin residues in porcine muscle tissue by a multipenicillin analytical method: European Collaborative Study.
2002 Jul-Aug
Improved brain delivery of benzylpenicillin with a peptide-vector-mediated strategy.
2002 Jun
Primary (isolated) meningococcal pericarditis.
2002 Jun
Fatality after an injection of Bicillin into the tonsillar fossa during an adenotonsillectomy.
2002 Mar
Characterization of specific IgE response in vitro against protein and drug allergens using atopic and normal donors.
2002 Mar
Evaluation of the new VITEK 2 system for determination of the susceptibility of clinical isolates of Streptococcus pneumoniae.
2002 Mar
Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions.
2002 Mar
Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney.
2002 May
Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.
2002 May
[Use of antibiotics in general practice and at the Clinic for Infectious Diseases].
2002 May-Jun
beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin.
2002 Nov
Minimum inhibitory concentrations of 20 antimicrobial agents against Staphylococcus aureus isolated from bovine intramammary infections in Japan.
2002 Nov
Quality control of antibiotics before the implementation of an STD program in Northern Myanmar.
2002 Nov
Mechanism of the reduced elimination clearance of benzylpenicillin from cerebrospinal fluid in rats with intracisternal administration of lipopolysaccharide.
2002 Nov
Acyl-intermediate structures of the extended-spectrum class A beta-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin.
2002 Nov 29
[Antimicrobial susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolated in major hospitals in Nagano Prefecture].
2002 Oct
Fatal outcome from meningococcal disease--an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin.
2002 Oct
Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain.
2002 Oct
Modulation of GABA(A) receptor-mediated currents by benzophenone derivatives in isolated rat Purkinje neurones.
2002 Sep
Biochemical characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa 802.
2002 Spring
Benzylpenicillin differentially conjugates to IFN-gamma, TNF-alpha, IL-1beta, IL-4 and IL-13 but selectively reduces IFN-gamma activity.
2003 Feb
High-performance thin-layer chromatography-bioautography for multiple antibiotic residues in cow's milk.
2003 Feb 5
Insights into the acylation mechanism of class A beta-lactamases from molecular dynamics simulations of the TEM-1 enzyme complexed with benzylpenicillin.
2003 Jan 22
Patents

Sample Use Guides

Serious infections due to susceptible strains of streptococci (including S. pneumoniae): 5 to 24 million units/day depending on the infection and its severity administered in equally divided doses every 4 to 6 hours Anthrax: Minimum of 8 million units/day in divided doses every 6 hours. Higher doses may be required depending on susceptibility of organism Actinomycosis: 1 to 6 million units/day Diphtheria (adjunctive therapy to antitoxin and for the prevention of the carrier state): 2 to 3 million units/day in divided doses for 10 to 12 days Listeria infections, Meningitis: 15 to 20 million units/day for 2 weeks
Route of Administration: Other
It was studied the antioxidant activity of penicillin G (PG) through its reactivity towards reactive oxygen species (superoxide anion radical, O2•̅; hydroxyl radical, HO• ; peroxyl radical, ROO• ; hydrogen peroxide, H2 O2 ; DPPH• ) using various in vitro antioxidant assays with chemiluminescence (CL) and spectrophotometry as measurement techniques. In hydroxyl radical assays , PG was found to inhibit the CL signal arising from the Fenton-like reaction in a dose-dependent manner with IC50 = 0.480 ± 0.020 mM. The highest reactivity of PG among the tested penicillins towards the HO radical was confirmed in the deoxyribose degradation assay.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:16:27 GMT 2023
Edited
by admin
on Fri Dec 15 16:16:27 GMT 2023
Record UNII
17R794ESYN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENICILLIN G PROCAINE
GREEN BOOK   MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
Procaine benzylpenicillin [WHO-DD]
Common Name English
BENZYLPENICILLIN PROCAINE
Common Name English
PENICILLIN G PROCAINE [VANDF]
Common Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3,3-DIMETHYL-7-OXO-6-((PHENYLACETYL)AMINO)- (2S,5R,6R)-, COMPD. WITH 2-(DIETHYLAMINO)ETHYL 4-AMINOBENZOATE, HYDRATE (1:1:1)
Common Name English
DURACILLIN A.S.
Brand Name English
BICILLIN C-R COMPONENT PENICILLIN G PROCAINE
Common Name English
PROCAINE BENZYLPENICILLIN
MART.   WHO-DD   WHO-IP  
Common Name English
PROCAINI BENZYLPENICILLINUM [WHO-IP LATIN]
Common Name English
PROCAINE PENICILLIN G MONOHYDRATE
Common Name English
PENICILLIN G PROCAINE [USP MONOGRAPH]
Common Name English
PENICILLIN G PROCAINE COMPONENT OF BICILLIN C-R
Common Name English
4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID, 3,3-DIMETHYL-7-OXO-6-((PHENYLACETYL)AMINO)-, (2S-(2.ALPHA.,5.ALPHA.,6.BETA.))-, COMPD. WITH 2-(DIETHYLAMINO)ETHYL 4-AMINOBENZOATE (1:1) MONOHYDRATE
Common Name English
PENICILLIN G PROCAINE [USP-RS]
Common Name English
PROCAINE PENICILLIN G
Common Name English
PROCAINE BENZYLPENICILLIN [WHO-IP]
Common Name English
CRYSTICILLIN A.S.
Brand Name English
PENICILLIN G PROCAINE [ORANGE BOOK]
Common Name English
PFIZERPEN-AS
Brand Name English
PENICILLIN G PROCAINE [MI]
Common Name English
PENICILLIN G PROCAINE [GREEN BOOK]
Common Name English
PROCAINE PENICILLIN
Common Name English
PROCAINE BENZYLPENICILLIN [MART.]
Common Name English
(2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENYLACETAMIDO)-4-THIA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID COMPOUND WITH 2-(DIETHYLAMINO)ETHYL P-AMINOBENZOATE (1:1) MONOHYDRATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1500
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
CFR 21 CFR 526.1696B
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
WHO-VATC QG51AG01
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
CFR 21 CFR 526.1696C
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
WHO-ATC J01CE09
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
CFR 21 CFR 558.145
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
CFR 21 CFR 526.1696A
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.1
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
CFR 21 CFR 522.1696
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
WHO-VATC QJ51RC04
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
CFR 21 CFR 522.1696A
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
WHO-VATC QJ01CE09
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
CFR 21 CFR 522.1696C
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
CFR 21 CFR 526.1696D
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
CFR 21 CFR 558.145
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
WHO-VATC QJ51CE09
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
WHO-VATC QJ51CE59
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
CFR 21 CFR 522.1696B
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
WHO-VATC QJ51RC23
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
Code System Code Type Description
CAS
6130-64-9
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
WIKIPEDIA
PROCAINE BENZYLPENICILLIN
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
CHEBI
52154
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
RS_ITEM_NUM
1502552
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
DRUG BANK
DB09320
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
LACTMED
Procaine Penicillin G
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
RXCUI
7983
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID40210207
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
EVMPD
SUB22648
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
ALTERNATIVE
MESH
D010402
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
MERCK INDEX
m8476
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY Merck Index
FDA UNII
17R794ESYN
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
EVMPD
SUB00752MIG
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PENICILLIN G PROCAINE
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Slightly soluble in water; soluble in ethanol (~750 g/l) TS. Category: Antibacterial drug. Storage: Procaine benzylpenicillin should be kept in a tightly closed container and protected from light. Labelling: The designation sterile Procaine benzylpenicillin indicates that the substance complies with the additional requirementsfor sterile Procaine benzylpenicillin and may be used for parenteral administration or for other sterile applications. Additional information: Solutions of Procaine benzylpenicillin are dextrorotatory. It is readily decomposed by acids, alkalis, andoxidizing agents. Even in the absence of light, it is gradually degraded on exposure to a humid atmosphere, the decompositionbeing faster at higher temperatures.
ChEMBL
CHEMBL1628385
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
DAILYMED
17R794ESYN
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
SMS_ID
100000088581
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
DRUG CENTRAL
4459
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
NCI_THESAURUS
C87370
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
PUBCHEM
22502
Created by admin on Fri Dec 15 16:16:27 GMT 2023 , Edited by admin on Fri Dec 15 16:16:27 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
ACTIVE MOIETY